Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326108 | 0.81 | MAPT (0.53) | RAB9ALMNAPTPN7DUSP3HTT | |
| SCHEMBL19378588 | 0.79 | LMNA (0.53) | NPC1LMNAGAAHTTMAPT | |
| SCHEMBL2775341 | 0.78 | LMNA (0.51) | SMN1; SMN2RAB9ANPC1LMNAGAA | |
| SCHEMBL19378463 | 0.77 | HDAC4 (0.40) | SMN1; SMN2RAB9ANPC1LMNAMAPT | |
| SCHEMBL17063968 | 0.76 | KAT6A (0.48) | SMN1; SMN2RAB9ANPC1LMNAPKM | |
| SCHEMBL642419 | 0.76 | CES2 (0.52) | RAB9ANPC1GAANFE2L2MAPT | |
| SCHEMBL16952707 | 0.76 | PIN1 (0.44) | SMN1; SMN2RAB9ANPC1LMNAPKM | |
| SCHEMBL4300383 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1LMNAPKM | |
| Iodide SCHEMBL6757843 | 0.75 | SMN1; SMN2 (0.40) | SMN1; SMN2RAB9ANPC1LMNAPKM | |
| SCHEMBL3459483 | 0.74 | F2R (0.38) | LMNAPKMHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| CN-104478821-B | Oxadiazole diaryl compounds | 默克雪兰诺有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-2193126-A1 | OXADIAZOLE DIARYL COMPOUNDS | Merck Serono S.A. (CH) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | SMN1; SMN2 1889/4885RAB9A 2114/4885NPC1 4730/4885 |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | SMN1; SMN2 1480/4885RAB9A 1744/4885NPC1 4703/4885 |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | SMN1; SMN2 1397/4885RAB9A 1833/4885NPC1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.